This week's column sees two Merck & Co. VPs move to Neostem and Covance, plus changes at Harlan and Aesica.
Merck VP of clinical research Barry J. Goldstein has moved to contract research organisation Covance, where he will become VP and global therapeutic area head of the expanded cardiovascular, metabolic, endocrine and renal unit. He will also join Covance’s medical and scientific affairs leadership team.
Ken Somberg, Covance’s chief medical officer, told Outsourcing-Pharma.com Goldstein had been chosen for his significant experience.
“Dr Goldstein brings significant endocrinology, metabolism, and broad drug development experience and knowledge to Covance,” said Somberg.
“With an extensive academic, medical and research background, he is a leader in the field of diabetes mellitus and endocrinology. He will build on our vision and work these key areas, and provide important scientific insight to our colleagues and our sponsors.”
Covance has expanded its cardiovascular and metabolic research in recent years, including through lipid trials and large cardiovascular outcomes studies. It is currently executing diabetes mellitus-related clinical trials. However yesterday it announced the sale of an “underperforming” genomics lab in Washington State to LapCorp.
Copyright - Unless otherwise stated all contents of this web site are © 2016 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions